Kornimate/medical-research-clean huggingface dataset:
supa mobility: supporting physical activity for mobility in mobility-limited older adults

Conditions: Limitation, Mobility; Older Adults

Summary: the goal of this randomized controlled trial is to investigate the effectiveness of a health-coaching intervention to improve physical activity in older adults with limited mobility when compared to a control, health education group.

a total of 290 older adults with limited mobility will be randomized to either a 26-week health coaching program or health education program. outcomes will be assessed at baseline, 13-weeks, 26-weeks (end of intervention), and 52 week (6-month follow-up period).

Eligibility criteria:
inclusion criteria: * scored ≤ 9/12 on the sppb * are able to complete the 400-m walk in ≤ 15 minutes without sitting or physical assistance from another person or walker (use of cane is acceptable) * scored 22/30 or higher on the mini-mental state examination (mmse) * have no significant functional impairment as indicated by a score of 6/8 or higher on the lawton and brody instrumental activities of daily living scale * are able to safely engage in mvpa as indicated by the par-q+ and by the family or study physician as necessary * are community-dwelling * are able to provide written informed consent. exclusion criteria: * are diagnosed with dementia or stroke * self-report engaging in mvpa ≥ 10 minutes per week in the prior 3 months * are unable to understand, speak, and read english proficiently

Keywords: physical activity health coaching exercise limited mobility
micromanaging human sleep physiology to treat sleep apnea and other disorders

Conditions: Sleep Apnea Obstructive (OSA)

Summary: this study will examine whether a combination of breathing training during wake and targeted reactivation of the training during sleep can induce breathing changes during sleep and subsequent cognitive benefits during wake. participants with obstructive sleep apnea (who have not yet been treated for sleep apnea) will be recruited. participants will engage in breath training for one week in their own homes and to record their sleep at home using commercially available mobile devices and subsequently have their sleep monitored for one night of polysomnography recordings plus targeted reactivation in a laboratory setting.


Eligibility criteria:
inclusion criteria: 1. right-handed, english-speaking adults, 18-60 years old who report normal hearing during sleep 2. participants with suspected obstructive sleep apnea (osa) (including those who have been diagnosed by a physician and those whose self-reported symptoms of osa on the stop-bang questionnaire classify them as being "individuals with intermediate to high risk". 3. no report of any other sleep disorder besides osa. 4. no report of any neurological or cardiometabolic diseases or disorders. 5. not currently under active treatment for sleep apnea. 6. bmi ≤ 40.

Keywords: sleep sleep apnea obstructive (osa)
ionized magnesium balance during hemodialysis session

Conditions: Chronic Kidney Diseases

Summary: aim of this study is to evaluate in a population of chronic kidney disease patients on dialysis (stage 5d) the balance of total and ionized magnesium according to different types of dialysate used in clinical practice (acetate + mg 0.50 or 0.75 mm vs citrate + mg 0.50 ou 0.75 mm)


Eligibility criteria:
inclusion criteria: * chronic kidney disease patient on dialysis (stage 5d) for more than 1 month * anuric patient exclusion criteria: * patient protected by law * patient under guardianship ou curatorship * patient deprived of liberty

Keywords: chronic kidney disease patient on dialysis (stage 5d) extracorporeal purification ionized magnesium
genetic study of idiopathic scoliosis in a cohort of families (scogen)

Conditions: Scoliosis Idiopathic

Summary: this study will focus on a large cohort of multiplex families, to precisely identify candidate genes. the fact of have a large database (fifty families, collected by the principal investigator for more than two decades), will contribute to the discovery of genes of interest. it will also allow testing for the presence or absence of mutations found in other cohorts in previous studies. the main objective of this study is to identify genetic abnormalities associated with the presence and severity of idiopathic scoliosis, in families of scoliosis.


Eligibility criteria:
inclusion criteria: inclusion criteria for "sick" patients: * presence of idiopathic scoliosis, diagnosed by a clinical examination by an orthopedic doctor and confirmed by the presence of a cobb angle greater than 10 ° on radiographs of the spine * signed informed consent * affiliation to a social security scheme or beneficiary of such a scheme inclusion criteria for "healthy relatives": * be related to the first or second degree with at least 2 individuals suffering from idiopathic scoliosis, and whose family tree over 3 generations finds at least 3 cases of idiopathic scoliosis * do not present with scoliosis (clinical examination by an orthopedic doctor and x-rays of the spine). * affiliation to a social security scheme or beneficiary of such a scheme exclusion criteria: non-inclusion criteria for "sick" patients: * be part of one of the following categories of vulnerable people: protected adults, adults unable to express their consent and not subject to a protection measure, pregnant women, parturients and nursing mothers, people deprived of their liberty, people hospitalized without consent, people admitted to a health or social establishment for purposes other than research * suspicion of scoliosis secondary to clinical examination non-inclusion criteria for "healthy relatives": * be part of one of the following categories of vulnerable people: protected adults, adults unable to express their consent and not subject to a protection measure, pregnant women, parturients and nursing mothers, people deprived of their liberty, people hospitalized without consent, people admitted to a health or social establishment for purposes other than research * discovery of scoliosis during research (if scoliosis of an idiopathic nature: patient included in the cohort of patients, if secondary scoliosis: exclusion from the family). all patients : pregnancy in progress or desired with discontinuation of contraception (contraindication to the realization of x-rays).
a stand-alone therapeutic music-with-movement programme for people with cognitive impairment

Conditions: Cognitive Impairment

Summary: the number of people living with cognitive impairment is increasing at an exponential rate. more than 100,000 older people are living with dementia in hong kong. alarmingly, about 60% of long-term care residents or day-care centre users are living with dementia, nearly all of whom experience anxiety, depression, or other behavioural and psychological symptoms that place heavy demands on healthcare support and jeopardize their quality of life. a standalone music-with-movement system is developed by integrating innovative and communication technology to facilitate the delivery of an evidence-based music-with-movement intervention. the technology employed are music library, 6-axis motion-sensing music instruments, wireless charging, and rfid. this study aims to evaluate the changes in health outcomes (cognition, psychosocial well-being and perceived support) of older adults after receiving the service delivered by the trained staff using the standalone music-with-movement system.

methods: 1. aims and objectives: 1. to evaluate the feasibility of the system supporting staff from elderly care institutes in leading musical activities (i.e., recruitment, retention, and acceptability); 2. to evaluate the engagement of the participants in the intervention; and 3. to preliminarily examine the health conditions of older adults with cognitive impairment. 2. methods: 1. design: single-group pre-and-post-test design 2. participants: older adults with cognitive impairment. 3. setting: elderly care institutes, such as daycare centres, community centres, and/or nursing homes. 4. sample size: 750 participants. 5. outcomes: recruitment rate, attrition rate, acceptability, any adverse events, engagement in the intervention, health outcomes (social support, frailty, health-related qol, moca). 6. data analysis strategies: 7. ethical consideration: approval has been obtained from the university (hsears20211026009)

Eligibility criteria:
inclusion criteria: * older adults with cognitive impairment * in a stable medical condition exclusion criteria: * with critical medical or psychiatric problems * those with uncorrectable hearing impairment

Keywords: music-with-movement music intervention cognitive impairment dementia
carbetocin and oxytocin in elective caesarean section with high risk of postpartum hemorrhage

Conditions: Postpartum Hemorrhage

Summary: double blinded randomized controlled study

women will be randomized into two groups using computer-generated random number list. 264 dark colored envelops will be serially numbered containing the corresponding letter of the corresponding drug that will be used. group c: 132 women in the carbetocin group will receive a bolus of 100 μg intravenous injection at delivery of the anterior shoulder. group o: 132 women in the oxytocin group will receive 5 iu of oxytocin by slow intravenous injection at delivery of the anterior shoulder. * all patients will receive general anaesthesia. * operation will be carried out by a three year registrar (at least). * uterus will be repaired in situ. primary endpoint: is the amount of blood loss. * blood loss will be estimated using the change in hb% and hematocrit, the actual blood loss will be calculated using the following equation: * the actual blood loss equals the estimated blood volume x difference between the initial hematocrit and the final hematocrit / the initial hematocrit secondary endpoints include: 1. the need for additional uterotonic medication after carbetocin or oxytocin administration. - uterine tone and uterine fundus level (with respect to the umbilical point, up) will be monitored during cs, at the end of cs, 2 hours, 12 hours and 24 hours after delivery - additional uterotonic drugs, needed if sufficient uterine tone is not achieved within 5 minutes of oxytocin or carbetocin administration, will include: i. ergometrine 0.5 mg by slow intravenous injection. ii. misopristol 1000 micrograms rectally. 2. the need for blood transfusion or operative interventions related to pph - the need for blood transfusion or operative intervention (b-lynch sutures, uterine artery ligation, internal iliac artery ligation, hysterectomy) will be considered. 3. the change in hemoglobin and hematocrit post versus pre cs - the drop in hemoglobin level and hematocrit will be evaluated by comparing the hemoglobin concentration on admission and 24 hours after delivery. 4. the hemodynamic adverse effects and the cost-benefit of both drugs.

Eligibility criteria:
inclusion criteria: * multiple pregnancy * presence of uterine fibroid * previous myomectomy * presence of placenta previa * past history of pph * fetal macrosomia * polyhydramnios exclusion criteria: * hypertension * preeclampsia * cardiac, renal, liver diseases * epilepsy * history of hypersensitivity to carbetocin

Keywords: postpartum hemorrhage carbetocin oxytocin
pharmacotherapy dosing regimen in cocaine and opiate dependent individuals - 8

Conditions: Cocaine Abuse; Opiate Dependence

Summary: the purpose of this study is to examine two medications, modafinil and citalopram, in the treatment of cocaine dependent individuals who are maintained on methadone.

this is a 24-week, randomized, double-blind, placebo-controlled study examining two doses of modafinil (200 and 400 mg) and citalopram (20 and 40 mg) in the treatment of methadone maintained cocaine dependent individuals. participants will first be given methadone to determine its tolerated and effective doses. most participants will be able to reach a stable dose of methadone within 7 to 10 days of methadone initiation. when 80% of the projected dose of methadone has been achieved, participants will begin the medication regimen of modafinil or citalopram. modafinil will be given over a 7-day period. dosing of modafinil will begin at 200 mg and, depending on the individual, may increase to 400 mg. citalopram will be given in increasing doses, starting at 20 mg and increasing to 40mg.

Eligibility criteria:
inclusion criteria: * meets cocaine abuse and dependence criteria (as determined by the scid) * meets opiate dependence criteria (as determined by the scid) * in good general physical and psychiatric health (except for possible acute drug use related problems) exclusion criteria: * meets diagnostic criteria for other psychiatric disorders, including other forms of drug dependence (other than nicotine) * current cardiovascular disease (as determined by an electrocardiogram) * circumstances will not allow for completion of study (on probation or parole) * ethical constraints of supervision do not allow confidentiality (on probation or parole)

Keywords: cocaine abuse opiate abuse
addition of mgso4 or dexamethasone to bupivacaine on the prolongation of ultrasound-guided quadratus lumboram block

Conditions: Post Operative Pain

Summary: the goal of postoperative pain management is the provision of comfort, early mobilization and improved respiratory function without causing inadequate sedation and respiratory compromise, which can be achieved through using regional anethesia. this study aimed to assess the analgesic effect of adding dexamethasone or magnesium sulphate with bupivacaine in ultrasound-guided qlb to prolong its duration in patients undergoing open abdominal surgeries in the early postoperative period regarding pain relief after approval of the ethical committees in ain shams university hospitals, patients undergoing open abdominal surgeries were included in the study, and were divided into three groups (n=22; each); group m, d and group c. in group a, patients (n=22) received 20 ml bupivacaine 0.25% plus 5 ml of 10% mgso. in group b, patients (n=22) received 20 ml bupivacaine 0.25% plus 8 mg dexamethasone (2 ml) plus 3 ml 0.9% nacl. in group c (control), patients (n=22) received 20 ml bupivacaine plus 5 ml 0.9% nacl.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i or ii * aged 18 to 65 years * body weight ≥ 60 kg and ≤ 90 kg * scheduled for open abdominal surgeries exclusion criteria: * patients' refusal to participate in the study * history of allergy to the medications used in the study * hepatic disease * renal disease * known neurologic disorders * psychiatric disorder * chronic treatment with calcium channel blockers * hyper-magnesemia * coagulopathy * anatomical abnormalities * hemodynamic instability * local infection * suspected intra- abdominal sepsis
tobramycin administered by eflow rapid nebulizer: pharmacokinetic study

Conditions: Cystic Fibrosis

Summary: this study assesses the aerosol delivery characteristics (measured by nebulization time, serum and sputum tobramycin pharmacokinetic parameters) and safety of tobramycin administered for inhalation by pari eflow rapid electronic nebulizer (no compressor) vs. pari lc plus jet nebulizer (with compressor) in subjects with cystic fibrosis.


Eligibility criteria:
inclusion criteria: * male and female subjects aged 6 years or over at the time of screening, * chronically colonized with pseudomonas aeruginosa. * diagnosis of cystic fibrosis (cf) * ability to expectorate sputum samples on command. * ability to tolerate a 1-week washout interval with no inhaled tobramycin or other aminoglycoside treatment. * clinically stable in the opinion of the investigator. exclusion criteria: * inhaled or intravenous aminoglycosides within 7 days before study drug administration. * any investigational drug within 2 weeks before screening. * loop diuretics within 7 days before study drug administration. * current use of inhaled tobramycin delivered by the pari lc plus jet nebulizer without washout period of at least 1 week before entering the study. * women who are, or plan to become, pregnant during the course of the study. * serum creatinine or blood urea (bu) above the upper limit of normal for sex and age, or an abnormal urine analysis * known local or systemic hypersensitivity to aminoglycosides. other protocol defined inclusion/exclusion criteria may apply.

Keywords: cystic fibrosis, tobramycin, pari eflow, pari lc plus, nebulizer, pharmacokinetic
effects of clomiphene citrate ovulation induction on frozen embryo transfer

Conditions: Infertility, Female; Clomiphene Citrate

Summary: clomiphene citrate has been widely used for treatment of infertility for decades. although its anti-estrogenic effects leads to low pregnancy rate, clomiphene citrate is still a first-line treatment for ovulation induction because of its simple usage, low prices, no injection and low risk of ovarian hyperstimulation syndrome. clomiphene citrate shows high affinity with estrogen receptor, which inhibits endometrial proliferation, inevitably leads to a decline in endometrial receptivity, thus affecting the success rate of ivf. in that case, use clomiphene citrate for ovulation induction is lost more than gained based on fresh embryo transfer. but recently, some researchers have proposed to extend the time from ovulation induction to embryo transfer, and the increased level of estradiol can replace clomiphene citrate to combine with the receptor, so that the uterine environment is more conducive to pregnancy. therefore, use clomiphene citrate based on vitrification of embryo maybe a good way for treatment of infertility. at present, using frozen embryo transplantation after ovulation induction by clomiphene citrate is a common treatment, but few research has mentioned the best time for embryo implantation. the investigators research is to find the most appropriate time for frozen embryo implantation after using clomiphene citrate for ovulation induction.

this study receives patients from 2017 august to 2018 june who undergo art treatment at shanghai jiai genetics \& ivf institute and taken either cc or gnrh antagonist protocol(control group) for ovulation induction. the investigators will record every patients' age, bmi, serum e2, p, lh level, infertility factors and pregnancy outcomes, counted the implantation rate and clinical pregnancy rate, and then used spss software x2 test for statistical analysis, the significance was set at p\<0.05.the investigators will also make a correlation analysis about the serum hormone level and pregnancy outcomes.

Eligibility criteria:
inclusion criteria: women 18-40 years of age who are scheduled for ivf or icsi in our ivf institute while meeting the following criteria: 1. amh ≥ 2; 2. infertility factors: tubal factor, severe oligospermia, etc; 3. fet cycle; 4. cleavage stage embryo transfer (day 3). exclusion criteria: 1. bmi ≤ 18.4 or ≥ 25.0; 2. have pregnancy complications; 3. genital tract malformations, uterine cavity diseases, pcos; 4. endometriosis; 5. genetic diseases, severe somatic diseases, mental disorder.
platelet reactivity with fentanyl, morphine, or no narcotic

Conditions: Fentanyl; Platelet Reactivity

Summary: the goal is to determine whether fentanyl and morphine have similar effects in reducing aspirin's effect upon platelets in emergency department patients with chest discomfort. morphine has been shown to worsen outcomes in heart attack patients due to reduction of oral anti-platelet agent effectiveness and so many providers have switches to using fentanyl. however, it is largely unknown whether fentanyl has similar effects.

patients presenting to the emergency department with chest discomfort who are being administered aspirin will be offered enrollment in this study. at the time of their zero and two hour troponin we will also draw platelet aggregration studies to determine the effects of aspirin upon platelets. narcotic medicines slow the absorption of aspirin. morphine has therefore been shown to decrease the effectiveness of aspirin. many providers therefore use fentanyl instead, however little is known about the effects of fentanyl upon aspirin. we will therefore compare the platelet reactivity of patients receiving morphine, fentanyl, or no narcotics

Eligibility criteria:
inclusion criteria: * adult emergency department patients undergoing 0 and 2 hour troponin testing * administered aspirin within 30 minutes of the initial blood draw. * patient presented via private vehicle * provide informed consent * over the age of 18 exclusion criteria: * patients not expected to get a 2 hour troponin; * patients already on aspirin, clopidogrel, or stronger anti-coagulants; * patients who arrived via ems (emergency medical services) given it can be difficult to find the run reports to determine whether patient received fentanyl in the pre-hospital period; * pregnant patients; * patients on chronic narcotics; * patients already once enrolled in this study, * inability to provide consent in english
pet-ct in diagnosis of pancreatic cystic neoplasms

Conditions: Neoplasms; Pancreatic Cancer

Summary: preoperative diagnosis of pancreatic cystic lesions remains a difficult problem in clinical practice. at present, the treatment planning in pancreatic cystic neoplasms is significantly restricted by the limited preoperative diagnosis. ultrasonography (us), multidetector computed tomography (mdct) and magnetic resonance imaging (mri) are the conventional modalities in imaging of pancreatic cystic neoplasms, but by these methods the diagnostic accuracy still remains compromised. furthermore, recently encouraging results have been obtained in pancreatic cystic neoplasms using 18f-fluoro-2-deoxyglucose positron emission tomography (18f-fdg-pet) the aim of the current project is to evaluate the possibility to enhance the diagnostic accuracy by using the combined 18f-fdg-pet-ct imaging in patients with pancreatic cystic neoplasms by combining pet-ct with mri and mdct.

today, in clinical practice the diagnosis pancreatic cystic neoplasms are based on mdct, mri and ercp followed by surgical exploration. the information gained by conventional imaging modalities is restricted to the morphological details, which usually is insufficient for the definitive staging of the pancreatic cystic neoplasms. based on these previous studies, it seems that pet especially combined with ct modality could improve the diagnostic accuracy of the pancreatic cystic lesions. so far, there are only few cases published concerning the role of 18f-fdg-pet-ct in the differential diagnosis of cystic pancreatic lesions. therefore, more studies are needed to determine the role of combined 18f-fdg-pet-ct in the diagnosis of pancreatic cystic lesions. the aim of the current project is to evaluate the possibility to enhance the diagnostic accuracy by using the combined 18f-fdg-pet-ct imaging in patients with pancreatic cystic neoplasms by combining pet-ct with mri and mdct. the study consists of 20-30 patients with pancreatic cystic neoplasms. the patients enrolled in the study will be imaged by mdct, mri combined with magnetic resonance cholangiopancreatography (mrcp), endoscopic retrograde cholangiopancreatography (ercp) and 18f-fdg-pet-ct followed by surgery or follow-up. the data will be collected between 2011 and 2013.

Eligibility criteria:
inclusion criteria: * suspicion of pancreatic cystic neoplasm using us, mdct, mri and/or ercp * laparotomy planned because of the lesion * signed informed consent exclusion criteria: -

Keywords: pancreatic cystic lesion pet pet-ct diagnosis